ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $627 | -15.0% | 30,074 | -2.4% | 0.00% | -20.0% |
| Q2 2023 | $738 | +4.8% | 30,809 | -17.7% | 0.01% | 0.0% |
| Q1 2023 | $704 | +21.4% | 37,413 | +2.7% | 0.01% | +25.0% |
| Q4 2022 | $580 | -99.9% | 36,416 | -7.9% | 0.00% | -20.0% |
| Q3 2022 | $647,000 | +137.0% | 39,550 | +104.2% | 0.01% | +150.0% |
| Q2 2022 | $273,000 | -55.2% | 19,373 | -23.1% | 0.00% | -33.3% |
| Q1 2022 | $610,000 | +13.6% | 25,205 | +9.5% | 0.00% | +50.0% |
| Q4 2021 | $537,000 | +72.7% | 23,011 | +23.0% | 0.00% | 0.0% |
| Q3 2021 | $311,000 | -17.7% | 18,709 | +20.8% | 0.00% | 0.0% |
| Q2 2021 | $378,000 | +11.5% | 15,484 | +17.8% | 0.00% | 0.0% |
| Q1 2021 | $339,000 | -41.0% | 13,149 | +22.2% | 0.00% | -33.3% |
| Q4 2020 | $575,000 | +106.8% | 10,763 | +59.8% | 0.00% | +50.0% |
| Q3 2020 | $278,000 | +13.9% | 6,736 | -42.7% | 0.00% | 0.0% |
| Q3 2018 | $244,000 | -21.0% | 11,754 | -41.9% | 0.00% | 0.0% |
| Q2 2018 | $309,000 | -37.6% | 20,236 | -8.2% | 0.00% | -33.3% |
| Q1 2018 | $495,000 | -51.1% | 22,049 | -34.5% | 0.00% | -57.1% |
| Q4 2017 | $1,013,000 | +233.2% | 33,642 | +317.0% | 0.01% | +250.0% |
| Q3 2017 | $304,000 | +42.1% | 8,067 | +5.3% | 0.00% | +100.0% |
| Q2 2017 | $214,000 | -18.9% | 7,658 | -0.2% | 0.00% | -50.0% |
| Q1 2017 | $264,000 | +19.5% | 7,676 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $221,000 | -32.8% | 7,676 | -25.7% | 0.00% | 0.0% |
| Q3 2016 | $329,000 | -19.8% | 10,332 | -18.2% | 0.00% | -33.3% |
| Q2 2016 | $410,000 | +25.4% | 12,633 | +8.0% | 0.00% | +50.0% |
| Q1 2016 | $327,000 | +21.1% | 11,702 | +54.4% | 0.00% | 0.0% |
| Q4 2015 | $270,000 | -16.9% | 7,580 | -22.9% | 0.00% | -33.3% |
| Q3 2015 | $325,000 | +150.0% | 9,833 | +217.1% | 0.00% | +200.0% |
| Q2 2015 | $130,000 | +64.6% | 3,101 | +28.2% | 0.00% | 0.0% |
| Q1 2015 | $79,000 | +3.9% | 2,419 | +0.4% | 0.00% | 0.0% |
| Q4 2014 | $76,000 | +11.8% | 2,409 | -12.2% | 0.00% | 0.0% |
| Q3 2014 | $68,000 | +7.9% | 2,743 | -1.2% | 0.00% | 0.0% |
| Q2 2014 | $63,000 | -7.4% | 2,777 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $68,000 | +9.7% | 2,777 | +11.8% | 0.00% | 0.0% |
| Q4 2013 | $62,000 | -73.2% | 2,485 | -70.5% | 0.00% | -50.0% |
| Q3 2013 | $231,000 | +188.8% | 8,426 | +90.1% | 0.00% | +100.0% |
| Q2 2013 | $80,000 | – | 4,433 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |